Recanati/Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY.
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Am J Transplant. 2016 Nov;16(11):3278-3281. doi: 10.1111/ajt.13923. Epub 2016 Jul 18.
We report an HIV-positive renal transplant recipient with delayed graft function who was converted from tacrolimus to belatacept in an attempt to improve renal function. The patient had kidney biopsies at 4 and 8 weeks posttransplant that revealed acute tubular necrosis and mild fibrosis. After 14 weeks of delayed function, belatacept was initiated and tacrolimus was weaned off. Shortly after discontinuing tacrolimus, renal function began to improve. The patient was able to discontinue dialysis 21 weeks posttransplant. HIV viral load was undetectable at last follow-up. To our knowledge, this is the first report of belatacept use in a patient with HIV.
我们报告了一例 HIV 阳性的肾移植受者，他在移植后出现了延迟的肾功能，为了改善肾功能，他从他克莫司转换为贝利尤单抗。该患者在移植后 4 周和 8 周进行了肾活检，结果显示急性肾小管坏死和轻度纤维化。在延迟功能 14 周后，开始使用贝利尤单抗并逐渐停用他克莫司。停用他克莫司后不久，肾功能开始改善。患者在移植后 21 周停止透析。最后一次随访时，HIV 病毒载量无法检测到。据我们所知，这是首例报道 HIV 患者使用贝利尤单抗的病例。
